Pharma Journalist

5th Medicinal Chemistry & Protein Degradation Summit
2020-11-16 - 2020-11-17 | London, UK
This Summit will focus its attention to some of the leading issues in Medicinal Chemistry today. This year the conference has expanded its coverage on protein degradation and will have a dedicated track running across both days to explore the cutting-edge research taking place in this exciting area.
The integration of AI and machine learning into the medicinal chemistry process is tackled in another track at the meeting with numerous case studies into how this developing technology is being utilized by industry leaders including Exscientia, Insitro and Bayer. This compliments the co-located informatics and AI meeting, which can be attended at any time, and examines artificial Intelligence in other parts of the drug discovery timeline.
Finally, the conference will be looking into recent advances and case studies in phenotypic screening and novel approaches to DNA encoded libraries within a dedicated track.
With dedicated space in the schedule to network, this conference is the ideal forum to share knowledge and build partnerships.
Visit the event page to download the full agenda.

2nd Annual Proteome- Targeted Drug Discovery Summit – Digital Event
2020-11-16 - 2020-11-18 | Virtual Event
With about 85% of the proteome currently undrugged, accessing these targets that are, at present, extremely difficult to drug, has prevented researchers from achieving desired clinical successes.
The 2nd Proteome- Targeted Drug Discovery Summit will unite large pharma and innovative biotech, as well as key opinion leaders in academia, to develop robust structural and biochemical tools to open up the full therapeutic opportunity held within the entire proteome. Identify and validate novel druggable sites and optimize structure-guided fragment-based drug design of small molecules with improved potency, selectivity, and physio-chemical properties.

Join the leading experts from the biopharmaceutical industry and academia to enhance your existing structural, chemical and computational toolbox and explore how these innovative technologies can be uniquely employed to target the entire proteome and advance your small molecule drug discovery pipeline.
Key Reasons to Attend Include

Utilize next-generation chemical biology platforms for novel target target identification with insights from Biogen, Merck & AstraZeneca
Expand the druggable proteome through next-generation screening platforms, with insight from GSK, PhoreMost & Ribon Therapeutics
Leverage innovative chemical probes to accelerate fragment-based lead generation, with insights from Novartis & The Weizmann Institute of Science
Harness structure-based computational technologies to successfully target protein-protein interactions, with insights from RAPT Therapeutics
Give rise to novel therapeutic modalities to drug the undruggable, with insights from Silicon Therapeutics& AbbVie

To know more about 2nd Annual Proteome- Targeted Drug Discovery Summit please click here.

4th Annual Antifibrotic Drug Development Summit
2020-11-16 - 2020-11-18 | Virtual Event
Solving the Translational Drug Development Gap, From Fibrotic Mechanisms to Clinically Effective Therapeutics.
Now in its 4th year, the digital AFDD summit is the industry’s definitive guide to turning mechanistic understanding of fibrosis into clinically effective therapeutics across disease areas. With 3 days of in-depth cutting-edge case studies and the highest calibre of discussions from cross-disciplinary fibrosis heavy-weights, AFDD will bridge the current translational gap to anti-fibrotic drug development success
Join 100+ fibrosis experts at this fully digital event to build a comprehensive network with like-minded peers and hurdle your translational drug development challenges to accelerate the development of more clinically effective drugs.
To know more about 4th Annual Antifibrotic Drug Development Summit please click here.

3rd Lifecycle Management for Combination Products Summit
2020-11-16 - 2020-11-18 | Virtual Event
The 3rd Lifecycle Management for Combination Products Summit is the only dedicated meeting focusing on Lifecycle Management (LCM) and perfecting design control. This year the meeting will unite senior combination products leaders online to discuss strategies and lessons learned to help you ensure commercial competitiveness in the combination product markets. From quality and product development, to CMC and regulatory affairs, our experts speakers will help you delve into how to produce a quality and safe combination product, implications of EU MDR and the final implementation phase of post-market surveillance reporting.
To know more about 3rd Lifecycle Management for Combination Products Summit please click here.

Clinical Operations in Oncology Trials USA 2020: Virtual Conference
2020-11-17 - 2020-11-18 | Virtual Event, CA
As the industry grapples with unprecedented challenges, join us for our first ever Clinical Operations in Oncology Trials USA Virtual Experience brought to you directly in the comfort of your home! Bringing together experts from across the country to discuss the latest innovations in technology, regulatory affairs as well as discover new opportunities through adaptive approaches and methods to run successful clinical trials.

To know more about Clinical Operations in Oncology Trials USA 2020 please click here.

CRISPR 2.0
2020-11-17 - 2020-11-19 | Digital Congress
Discover the Next Generation of CRISPR Tools to Enhance Specificity, Reduce Off-Target Effects & Transform Gene Editing into a Clinical Reality
CRISPR is one of the most powerful discoveries of the last decade.
In a remarkably short space of time, ‘classic’ CRISPR-Cas9 has established itself as a reliable tool in the genomics toolbox, which leads to the question: what’s next?
CRISPR 2.0 is the industry-leading meeting dedicated to answering this question by showcasing only the latest and greatest innovations in CRISPR technology, from the potential of prime editing through to epigenome editing to treat chronic pain.
Don’t get left behind. Join leading pharma and biotech companies pioneering CRISPR-based therapeutics into the clinic and academic organizations breaking new ground in establishing novel CRISPR tools.
Join us to usher in the next generation of safe, targeted and effective genome editing.
For more information on the conference, visit https://ter.li/ok8ifs
“Thank you for having me. I have attended all CRISPR Congresses and they keep getting better” John Sundman, Past attendee, CRISPR Event Series
” I greatly enjoyed the diversity and topic coverage of the talks, thanks for putting together an excellent program!” Christina Kolodzy, Past attendee, CRISPR Event Series
“A high-quality worthwhile conference, attended by first rate professionals. I learned more than I anticipated I would” Past attendee, CRISPR Event Series

CPhI & P-MEC China Virtual Expo Connect
2020-11-18 - 2020-12-18 | Virtual Event powered by CPhI China & Pharmasources.com
As well as the physical CPhI & P-MEC China 2020 show that will take place in Shanghai from 16th – 18th December, a digital extension of the event – known as “Virtual Expo Connect” – will take place online from November 18th – December 18th, allowing you to do business in China, no matter your location. The hybrid “Virtual Expo Connect” offers an online alternative for international visitors unable to travel to the physical show in China due to travel restrictions, adding valued services and infinite opportunities to connect, learn, trade and grow.
CPhI & P-MEC China Virtual Expo Connect
A hybrid offline-2-online platform for global pharma professionals
Nov 18 – Dec 18, 2020
To know more about CPhI & P-MEC China Virtual Expo Connect please click here.

Digital Pathology & AI Congress: USA
2020-11-19 - 2020-11-20 | New York, USA, United States
This meeting has a reputation for providing an outstanding networking experience. Discover how to effectively harness gains such as reducing lab costs, improving links with other laboratories and scientists, and minimizing human error.

Topics covered on the agenda include:

How AI is being applied to primary diagnosis and clinical research.
AI for image analysis and advancements in imaging
Computational pathology and AI
Implementation: practicalities and costs
Pharma and industry case studies

With dedicated space in the schedule to network, this conference is the ideal forum to share knowledge and build partnerships.
Visit the event page to download the full agenda.

Women and Infant Health Microbiome Congress
2020-11-19 - 2020-11-20 | London, UK
With dedicated space in the schedule to network, this conference is the ideal forum to share knowledge and build partnerships.
Visit the event page to download the full agenda.

Digital Agenda Revealed: 9th HPAPI Summit
2020-11-19 - 2020-11-20 | Virtual Event
As the world around us evolves, we want to ensure we can still unite you and your peers in highly potent API development and manufacturing.
We are excited to have transformed the 9th HPAPI Summit into a fully digital meeting running on November 19-20.
Thanks to our dedicated speakers, we’re still able to deliver the high-quality content and networking opportunities that you need to advance your high potent strategy in your company, from development to containment to EHS and outsourcing.
And the best part? As a giving back to our long standing HPAPI community, pharma, biotech and academia can now register for free!
Solution provider rate starts from $1,259, register by August 7 to save up to $280.
Download the new digital event program here.
Here’s a glimpse at some of the expert speakers confirmed to present:

Christopher Sears, Senior Director, CMC Tarveda Therapeutics
Cornelia Rudolph, Clean Water DG Environment, European Commission
Graeme McKilligan, Lead Senior GMDP Inspector, MHRA
Mirjam Sax, Principal Site Manager, Genentech
Dave Eherts, Vice President Global EHS, Allergan
Andrew Hopkins, Director, Operation Quality, QA Audit & Compliance, AbbVie
John Roosa, Director, New Technology Development & Industrial Hygiene Engineer, Merck

Our bespoke virtual conference platform will allow you to network with industry colleagues, evaluate new suppliers and the latest technology HPAPI containment and participate in live Q&A with speakers. For more details see here.
We hope to see you there!

In-House Impact: Life Sciences 2020 – Virtual Event
2020-11-19 - 2020-11-20 | Virtual Event
Redefining In-House Counsel as Innovator & Strategic Partner, Maximizing & Benchmarking Legal Business Value to Set the New Standard for Today’s Life Sciences Lawyer.
In-House Impact works because it connects you with the most forward-thinking legal leaders taking the most radical steps to maximize the business value they add as strategic business partners.
With thought-provoking case studies, action-led discussions and ensuring every story shared is evidenced by the business improvement it delivers, we guarantee that your time and your money are well spent.
This conference isn’t just unique in offering an industry-specific platform for the most progressive legal leaders to maximize their own business value; it’s also unique in that it rips up the rulebook of traditional conferences.
We believe the traditional conference format is no longer fit for purpose, so we started from scratch.

Here’s how it works:
When you look at the event agenda, you will see three main types of sessions:

Discover sessions offer you the chance to hear the boldest legal leaders in Life Sciences sharing the stories of what they’re doing to maximize the impact of their team
Develop sessions provide you with the unique opportunity to have your burning questions answered in a room full of your peers and move beyond the ‘what’ and the ‘why’ to get to the ‘how’
Action sessions divide the audience by same-level seniority, and are designed to help you discuss challenges with peers, and decide what you are going to change in order to add as much value to the business

In-House Impact: Life Sciences is a new event, both designed by and for General Counsels of Life Sciences companies, from smaller start-ups to large pharmaceuticals.
For more information visit https://ter.li/cata3o, or contact the team via email at info@hansonwade.com.

*NEW* Translating Documentation & Communication Clinical Research: Virtual Conference
2020-11-24 | Virtual Event, CA
This one-day online event will deliver top-quality content and engagement covering all aspects of language operations for clinical research: clinical trial protocols, informed consent, site documents, regulatory submissions and correspondence, labeling, IFUs, patient correspondence, and much more.

To know more about Translating Documentation & Communication Clinical Research please click here.

Cost-efficient and Green Manufacturing of Peptides thanks to Molecular Hiving™ Technology
2020-11-26 | Online Webinar
HOSTED BY: Bachem Group
LED BY: Dr. Wolfgang Seufert, Director Production III – Process Development, Bachem
Bachem and Jitsubo CO., Ltd. recently announced the signature of an exclusive Licensing Agreement for Jitsubo’s Molecular Hiving™ Technology. Under the License agreement, Jitsubo will develop selected manufacturing processes using their Molecular Hiving™ Technology and transfer these processes to Bachem. Bachem will further optimize, scale up and produce for commercial applications.

Molecular Hiving™ is a tag-assisted liquid-phase peptide synthesis technology developed by Professor Kazuhiro Chiba at Tokyo University of Technology and Agriculture. This technology uses a hydrophobic tag, which is applied in the same way as the resin for solid-phase peptide synthesis (SPPS) processes. The same standard Fmoc amino acid derivatives as for SPPS are applied for assembling the peptide chain. However, all couplings and cleavages of the Fmoc protecting group are performed in solution allowing for fast reactions and direct in-process controls, e.g. by HPLC. Excess reagents as well as coupling and cleavage related by-products are solely removed by aqueous extractions. Therefore, intermediate isolation of the tag-bound peptide and excessive washing steps are not required for Molecular Hiving™ Technology.
In this webinar, the speaker will guide you through the individual steps for synthesis of peptides applying Molecular Hiving™ Technology. You will learn about the scalability and the substantial advantages of this technology regarding efficiency and towards greener manufacturing, as solvent consumption and material requirements are significantly reduced compared to conventional SPPS processes. Molecular Hiving™ also allows the synthesis of peptides without the use of solvents and reagents which are carcinogenic, mutagenic, or toxic to reproduction (CMR substances). This makes peptide products manufactured by this technology highly attractive for the pharmaceutical and cosmetics industry.
Benefits for Joining the Webinar:

Hear about Bachem’s partnership with Jitsubo
Discover how to synthesize peptides by Molecular Hiving™ Technology
Explore the advantages and the environmental benefits of Molecular Hiving™ Technology
Learn about manufacture of peptides without CMR solvents and reagents

Who should attend?
Scientists in Pharma, Biotech, Cosmetics industry, and Universities including:

Research Scientists and Associates
PostDocs and PhDs
Scientific Advisors
Directors of Research and Development

Other Professionals in the Life Sciences including Product Managers and Marketing Managers

2nd Annual Gene Therapy Analytical Development | Running Digitally for 2020
2020-11-30 - 2020-12-03 | Virtual Event
Optimizing Analytical Methods to Guarantee Safe, High Quality, Consistent & Efficacious Gene Therapy Products
In the context of rapid gene therapy progress and mounting regulatory scrutiny, the 2nd Annual Gene Therapy Analytical Development Summit will virtually unite large pharma and innovative biotechs to discuss the full and comprehensive range of analytical tools required to guarantee the consistency, quality and safety of gene therapy products.

Focused specifically on addressing the unique analytical challenges posed by gene therapy vectors, this technical scientific conference will unite the Analytical Development, QC, CMC, and Process Development leaders grappling with these challenges first-hand.
Incorporating tracks taking a deep dive into bioassays, molecular biology, and analytical chemistry, this is your opportunity to gain extensive technical information enabling you to solve the exact challenges you’re encountering. Enhance your existing analytical methods and explore innovative novel tools to support safe and effective gene therapy development.
To know more about 2nd Annual Gene Therapy Analytical Development please click here.

2nd RNA Editing Summit 2020
2020-12-01 - 2020-12-03 | Virtual Event
RNA Editing is reaching an inflection point and is rapidly being discussed, invested in and adopted by the industry.
This year, in an all new digital format, the timely 2nd RNA Editing Summit returns as the only industry led meeting showcasing the recent developments of RNA editing mechanisms and dedicated to realizing the research and therapeutic opportunity of RNA editing as quickly as possible.

This meeting offers a wealth of relevant content covering everything from basic RNA biology and the fundamentals of RNA editing through to mitigating against off target activity to the plethora of clinical applications.
Join industry leaders from the likes of InsideOutBio, Edigene, Locano Bio and more to:

Hear the current strategies of site directed RNA editing from A – I to C – U to CRISPR based
Understand how to mitigate off target-activity without critically effecting the efficiency of the on target edit in the transcript
Ensure the safety and stability of your edit whilst maintaining efficiency and safe guard against potential toxic events
Assess how to develop RNA editing technologies in preclinical models to ensure the system works as intended in the human body
Delve into the different delivery mechanisms available to ensure the protein molecules that do the editing make it into the cells
Identify the latest clinical applications of RNA Editing, reviewing the structures and functions of ADARs, CRISPR CAS 13, APOBEC and their involvements in human diseases

To know more about 2nd RNA Editing Summit 2020 please click here.

Neuromuscular Drug Development Summit
2020-12-01 - 2020-12-02 | Virtual Event
Validate Clinically Meaningful Endpoints, Optimize Clinical Trial Design & Compare & Contrast Diverse Approaches to Accelerate the Discovery & Development of Meaningful Treatments for Patients in Need

The 3rd Neuromuscular Drug Development Summit presents a unique opportunity to:

Uncover the right outcome measures to use in your clinical trial and discover how to establish clinical meaningfulness with Biogen
Hear approaches to optimizing therapeutic efficacy in SMA, an innovative approach to trial design for real world SMA population and how combinatorial treatments may improve SMA treatment outcomes with Roche, PTC Therapeutics and John Hopkins University School of Medicine
Assess emerging neurophysiological methods for more quantitative, faster readouts and the need to explore digital capture tools to improve therapeutic R&D with Harvard Medical School and the Parent Project Muscular Dystrophy (PPMD)
Dissect various dosing strategies and discuss how to demonstrate a clear mechanistic route between dose, mechanisms of action and endpoints with NMD Pharma and Argenx
Evaluate the role of biomarkers, how regulatory agencies approach the integration of biomarkers in clinical trials and biomarker outcome measures outside dystrophin with ReveraGen Biopharma and the Critical Path Institut
Hear how Avidity Biosciences are developing an oligonucleotide antibody conjugate for the treatment of DM1

Uniting drug developers and academics from all corners of the world, the virtual Neuromuscular Drug Development Summit is your opportunity to discuss recent advances in this fast-evolving field, convey lessons learned and network to build long lasting partnerships.

7th Microbiome & Probiotics R&D & Business Collaboration Forum: Europe
2020-12-02 - 2020-12-03 | Rotterdam, The Netherlands
In response to COVID-19, this meeting will be hosted online using the latest digital technology. Network with your peers, ask questions of the speakers, and meet with the sponsors from the safety of your home or office.
This forum has a long-standing reputation for bringing together leading academic and industry microbiome researchers. Presentations will feature the latest research into the human microbiome as well as effective business and commercialization strategies for new products.
Topics covered on the agenda include:

IBD, Colitis, and Metabolic Diseases
Gut-brain axis
Women’s health
Skin & Cosmeceuticals
Personalized nutrition
Business Collaboration – Regulations & Investment
Probiotics & Prebiotics
Roundtable discussions

With dedicated space in the schedule to network, this conference is the ideal forum to share knowledge and build partnerships.
Visit the event page to download the full agenda.

Clinically Validated Digital Therapeutics Summit
2020-12-02 - 2020-12-03 | Virtual Event
As the world opens up to digital health, now is the time to design, develop & deliver clinically validated digital therapeutics to patients in need. Back for its 3rd year, the Clinically Validated Digital Therapeutics Summit will unite more stakeholders than ever before. Explore newcomers in the world of DTx, showcasing never before shared case studies. This meeting will solely focus on the actionable uses of digital therapeutics to deliver radically improved patient outcomes.
Integrating brand new lessons learned from the COVID 19 pandemic, the 2020 summit will drive the DTx industry forward with case studies that tackle a multitude of disease areas and therapeutic modalities, from prescription and chronic disease management to care bundles, concomitant therapy and preventive medicine. Covering the full spectrum, the 2020 summit will address challenges around clinical trials, regulatory approval, reimbursement and value application in healthcare.
View the Full Event Guide Here.

7th Digital Pathology & AI Congress: Europe
2020-12-03 - 2020-12-04 | London, UK
This meeting has a reputation for providing an outstanding networking experience in which you can discover how to effectively harness gains such as reducing lab costs, improving links between other laboratories & scientists and minimizing human error.

Over two days you will discover more about the latest advances and applications of digital pathology, including:

How artificial intelligence and machine learning is being applied to primary diagnosis and clinical research.
How the image-based information environment is transforming the laboratory.
AI for image analysis and advancements in imaging.
Computational pathology and AI.
Implementation: practicalities and costs.
Pharma and industry case studies.

With dedicated space in the schedule to network, this conference is the ideal forum to share knowledge and build partnerships.
Visit the event page to download the full agenda.

BioFIT 2020
2020-12-07 - 2020-12-10 | Virtual Event
Come and join us online for the 9th edition of BioFIT, from the 7th to the 10th of December 2020!
With the highest attending rate of TTOs, research institutes and academia together with big pharma, emerging and small biotech, diagnostics companies, pre-seed / seed / Series A investors, BioFIT is the leading partnering event in Europe for technology transfer, academia-industry collaborations and early-stage innovation deals in the field of Life Sciences. BioFIT is also the European marketplace for pre-seed, seed and Series A investment in Life Sciences.

KEY FIGURES:

1,400+ delegates
900+ organisations
40+ countries represented
1,000 deals generated in 2017

INSIDE THE EVENT:

A business convention with pre-qualified one-to-one meetings
Conferences and roundtable discussions
Oral presentations of start-ups and licensing opportunities stemming from academia
An exhibition area
Informal networking evenings

Across these 4 days of event, you will be able to e-meet and network with these attendees from the comfort of your home office. The one-to-one partnering meetings will be possible 24H a day.
You will also have access, for the conferences and the pitch sessions, to a mix of live and on-demand content during those 4 days and available for 30 days afterwards; and you will also have the opportunity to debate with the speakers and pitchers via interactive online chats.
Website: www.biofit-event.com
Registration: www.biofit-event.com/registration-for-biofit/
Contact: msatola@eurasante.com

2nd Annual Gene Therapy for Neurological Disorders | Running Digitally for 2020
2020-12-08 - 2020-12-10 | Vitual Event
Revolutionize the Development & Delivery of Neurological Gene Therapies
Returning this year as a digital meeting with an agenda designed with the field’s thought-leaders including Pfizer, Biogen, Voyager and Novartis, the 2nd Annual Gene Therapy for Neurological Disorders is the industry’s only meeting dedicated to solving your translational drug development challenges, enabling you to accelerate the development of your neurological gene therapy candidate.
Don’t get left behind. Attend this meeting to transform gene therapy delivery to the CNS, optimize translational modelling approaches and discover targeted, efficacious, and safe vectors to revolutionize the treatment of neurological disorders.
To learn more about Gene Therapy for Neurological Disorders please click here: https://ter.li/c610sy

3rd RNA-Targeted Drug Discovery Summit
2020-12-08 - 2020-12-10 | Digital Event
The 3rd RNA- Targeted Drug Discovery Summit returns as the most comprehensive and definitive event for the RNA targeting small molecule community to not only address key challenges of the field, such as successful determination and prediction of RNA structure and role in disease, but also to drive forward optimized strategies to improve target selection and gain pre-clinical proof of concept to drive the field forward towards translation into clinical development.

With numerous approaches emerging to demonstrate genuine viability in directly or indirectly targeting RNA with small molecules, join leading biopharmaceutical directors, VPs and C-level executives at the 3rd RNA- Targeted Drug Discovery Summit – your premier industry and translational focused conference dedicated to advancing pioneering RNA biology and drug discovery into a blockbuster RNA targeting small molecule therapeutic approach that improves patient outcomes.
The world of drug discovery and chemical probes is still protein-centric and developing highly selective small molecules targeting RNA is often considered to be an insurmountable challenge. This view is now changing given the recent progress and scientific breakthroughs in understanding the fundamental biology and function of RNA, opening the door to RNA targeted small molecule drug discovery.

Explore how to optimize medicinal chemistry insights & RNA biology to enhance robust translation with The Scripps Research Institute, Anima Biotech & Arrakis Therapeutics

Successfully target RNA via interfering with RNA-protein interactions/ Epitranscriptomics with insights from Storm Therapeutics, Accent Therapeutics & Saverna Therapeutics

Expand your knowledge of RNA structure, function & role in disease with insights from Yale University, H3 Biomedicine & Whitehead Institute for Biomedical Research

Advance identification & validation of viable RNA target sites for therapeutic intervention with insights from PTC Therapeutics & Duke University

Overcome binding, selectivity & drug-like challenges of small molecules targeting RNA with insights from Roche, University of California San Diego & Novartis

To know more about 3rd RNA-Targeted Drug Discovery Summit please click here.

Decentralized Clinical Trails Summit
2020-12-08 - 2020-12-09 | Virtual Event
Strengthen Your Operational and Compliance Protocols to Accelerate Technology-Enabled, Patient-Centric, and Cost-Efficient Decentralized Clinical Trials
With the potential to improve recruitment rates, simplify compliance, reduce drop-out rates, and speed-up your product’s time to market, decentralized clinical trials represent an opportunity to rethink and refresh how research studies are conducted, while keeping the patient at the heart of all trials.

Despite this, only a fraction of clinical trials are currently run as hybrid of virtual models. This is about to change. The age of decentralized clinical trials is here, and keeping pace with the rest of the industry means preparing your internal processes for the change.
Created in conjunction with clinical trial leaders from big and small pharma, forward thinking academics, and research institutes, the programme for this year’s Decentralized Clinical summit has been designed to help you to develop the toolkit you need to run successful decentralised trials. Join over 100+ peers this December to tackle issues such as: using digital tools and wearables, maintaining data quality and integrity, simplifying e-consent, optimising patient recruitment, restructuring project teams, rethinking trial design and undertaking study-model matching.
To know more about Decentralized Clinical Trails Summit please click here.

3rd Microbiome Movement – Skin Health & Dermatology Summit
2020-12-08 - 2020-12-10 | Digital Event
As the tools and technologies that are available to study the skin microbiome become cheaper and more accessible, the fundamental mechanisms that link the skin microbiome with skin health are becoming stronger. The demand for skin microbiome products is advancing rapidly which is only being reflected in the increasing number of products on the market that claim to modulate the microbiome.
Despite this growing opportunity, there are still a number of basic and clinical science that need addressing to ensure that industry researchers are creating products that demonstrate true impact in patients and consumers.

The 3rd Microbiome Movement – Skin Health & Dermatology Summit returns to unite leaders from academia and industry to address the unique challenges that working within the skin microbiome possesses, with the goal to accelerate microbiome-targeted therapeutics and cosmetics.
With discussions focusing on targeting the microbiome to treat inflammatory skin disease, exploring how pre, pro and post biotics can be optimized to improve skin health as well as a view into the regulatory and patent landscape; this opportunity is not to be missed. This is not to mention our new Pre-Conference Commercialization & Marketing Focus Day that will provide a deep dive into consumer education and product differentiation.
To know more about 3rd Microbiome Movement – Skin Health & Dermatology Summit please click here.

Medical Fair Asia 2020 Digital Edition
2020-12-09 - 2020-12-18 | Virtual Event, CA
MEDICAL FAIR ASIA 2020 Digital Edition is set to take place from 9 – 18 December 2020. The shift to a digital event for its 13th edition is in response to the dynamic situation of the COVID-19 pandemic, where travel and physical restrictions are still in effect globally.

As the leading medical and healthcare exhibition in the region, the well-established exhibition will feature the latest medical technology and innovations, and healthcare equipment and supplies for the Hospital, Diagnostics, Pharmaceutical, Medical & Rehabilitation sectors.
Moving from in-person interactions at a physical trade event to making virtual connections anywhere in the world, MEDICAL FAIR ASIA Digital Edition aims to deliver the onsite benefits of a trade fair but with all the convenience of an online experience.
MEDICAL FAIR ASIA is organised by Messe Düsseldorf Asia, the subsidiary of Messe Düsseldorf GmbH based in Germany and organiser of the world’s no. 1 medical fair – MEDICA. The exhibition is also a member of the MEDICAlliance, the global network for medical trade fairs worldwide.
For more information about Medical Fair Asia 2020 and to register, visit https://www.medicalfair-asia.com/

Pre-Filled Syringes and Injectable Drug Devices 2021
2021-01-13 - 2021-01-14 | Virtual Event
Device design, regulatory and strategic pathways for parenteral drug delivery
SMi is proud to present the 13th Annual Pre-Filled Syringes Conference on 13th and 14th January 2021.
The pre-filled syringes industry is growing at an exponential rate. With increasing demand for self-administration, a rise in biologics, large-volume delivery and the delayed EU MDR at the forefront of the field, SMi’s 13th annual event will bring you the key insights you need to grow and enhance your pre-filled syringes portfolio and discover what the future holds for the PFS and combination products industry.
Topics of discussion will include the latest updates on the EU MDR and Article 117, advances in novel drug products and biologics, parenteral packaging for pre-filled syringes, innovations in device design and platforms for combination products, lifecycle management and much more…

The two-day agenda offers you peer-to-peer networking with Global Product Managers, Senior PFS Engineers, Device Testing Managers, Heads of Late-Stage PFS Development and many more.
As Europe’s first Pre-Filled Syringes Conference of 2021, this event is not to be missed. We look forward to welcoming you to the conference in January.
BENEFITS OF ATTENDING:

Engage with senior industry opinion leaders presenting their experiences and case studies in innovative device design and advanced drug product formulation
Gain insights from notified body and competent authority representatives addressing key regulatory requirements
Understand how to optimize your lifecycle management strategy for a commercially successful device
Explore and benchmark against industry advances in device design through case studies and real-world examples

View the full agenda and speaker line-up online: www.pre-filled-syringes.com/pjwl
Plus, pre-conference workshops will be taking place on 12th January :
Workshop A: Digital Health – What are the real-world opportunities and potential barriers to adoption?
Workshop Leader: Andrew Dundon, Founder, PharMechceutics Ltd
08.30 – 12.00
Workshop B: Challenges and Drivers for Development of Long Acting Injectables
Workshop Leader: Joël Richard, Chief Development Officer, MedinCell
13.00 – 17.00
EARLY-BIRD RATES:

BOOK BY 30TH SEPTEMBER AND SAVE £400
BOOK BY 30TH OCTOBER AND SAVE £200
BOOK BY 30TH NOVEMBER AND SAVE £100

Registrations can be made on the event website at: www.pre-filled-syringes.com/pjwl
Chairs for 2020:

Bjørg Kaae Hunter, Department Manager, RA CMC & Device; RA NextGen Drug-Device,
Novo Nordisk
Alphons Fakler, Head Medical Device Risk Management, Novartis

Featured speakers:

Brian Holly, Head of Human Factors, Devices Centre of Excellence, Pfizer
Daniel Latham, Head Device Development & LCM, Novartis
Rene Holm, Head and Scientifi c Director, Drug Product Development, Liquids and Parenterals, Janssen
Stefano Martini, Responsible for Special Programs, Medical Devices Development, Sanofi
Sarah Tang, Regulatory Affairs Manager, Devices Division, MHRA
Abha Raveau violette, Device Manager, AstraZeneca
Vikas Jaitely, Director, Global Regulatory Affairs Transitional Medicine and Devices, Merck
Julia Frese, Director, TÜV SÜD
Clemens Günther, Director, Senior Expert Nonclinical Safety, Bayer
Jonathan Sutch, Technical Specialist, BSI

Additional Contact Info:
T: +44 (0)20 7827 6088
E: hsidhu@smi-online.co.uk
Follow us: @SMiPharm #PFSSMi

Onco Cell Therapy Global
2021-01-20 - 2021-01-21 | Virtual Event
Following the success of our first digital event in July with the likes of Carl June leading the keynote, the Onco Cell Therapy Summit is returning in its most interactive form ever with 20+ panel conversations, townhall meetings, roundtable sessions and coffee break style networking.

The Global Onco Cell Therapy Summit is an online event, 20th – 21st January 2021, that provides a platform for information sharing to enable the discovery, translation and commercialization of cell therapies in oncology by connecting senior representatives in pharma, biotechs and academia. The summit will address the research, regulatory, logistical and technical challenges that are holding back the field.
Delve into how thought leaders in cell therapy are addressing threats and opportunities to bring effective therapies to the market through:

Meeting efficacies and safety targets as well as the scale of demands.
Discovering the latest advances in the journey towards effective allogeneic and solid tumor targeting therapies.
Overcoming the challenging in scale up and automation of manufacturing
Round table discussions on vectors and the promise of non-viral approaches.
Reimbursement strategies and their link to the latest developments in safety trials and regulatory standards

Whilst bringing together the key decision makers for oncological cell therapies, this year’s summit will have an added focus on the data releases and mergers that are driving the surge of interest in harnessing alternative cell therapies in cancer treatments.
New for 2020 | Pre-event sessions:
25th Nov | Manufacturing roundtable | FREE to attend
15th Dec | ASH Review | FREE to attend
19th Jan | NK Day | Registrants only
Visit the website www.oncocelltherapyglobal.com for more details and to view the full agenda. (link to https://go.kisacoresearch.com/l/678123/2020-11-16/4r1xv). Don’t forget as a reader of Pharma Journalist, quote PJ10 for a 10% discount.

TGFβ for Immuno-Oncology Drug Development Summit
2021-01-26 - 2021-01-28 | Virtual Event
The world of TGFβ is at a tipping point within industry, for an explosion of data to come.
Exploring the wide array of approaches being utilized in pharma, biotech, and academia, the TGFβ for Immuno-Oncology Drug Development Summit is the ONLY industry-led event dedicated exclusively to exploring TGF-beta’s role in cancer therapeutics. This 3-day summit is your definitive meeting to delve into the core challenges of this complex target.

Don’t miss out on your chance to deepen your understanding of cell signaling mechanisms, change your view of the tumor microenvironment, and prepare your candidates for the clinic to ensure patient safety.
Join your peers this year to:

Hear from Scholar Rock on the selective inhibition of TGFβ1 activation with SRK-181, their phase 1 candidate
Discover the latest on Bintrafusp Alfa clinical trials from James Gulley at NCI, and Clinical Development from Yan Lan at EMD Serono

Explore the mechanism of action data from Novartis on their anti-transforming growth factor-beta antibody XOMA089
Get involved in Takeda, Scholar Rock, Oncotelic, and Sanofi’s debate the best TGF-beta isoform to target, combination vs monotherapy approaches, and the winning therapeutic approach
Contrast Small Molecule vs Antibody approaches to utilizing Integrin Inhibition with presentations from Morphic Therapeutic and Venn Therapeutics

To know more about TGFβ for Immuno-Oncology Drug Development Summit please click here.

4th Antigen Specific Immune Tolerance Summit (ASIT)
2021-01-26 - 2021-01-28 | Digital Event
The 4th Antigen Specific Immune Tolerance Digital Summit (ASIT) brings together industry representatives from the fields of autoimmunity, allergy, immuno-oncology and transplantation to tackle the complexities behind autoimmune disorders head on. With momentum building for antigen specific immunotherapies, ASIT 2021 will be the only antigen-specific summit offering thought-leading content to drive the field towards a more precise and ethical antigen-specific approach to drug development.

This is the industry’s definitive antigen specific drug development forum.
Across 3 packed days, thought leaders from Novartis, ImCyse, Harvard Medical School, Toleranzia, Toralgen will reveal insight, data, and lessons learned from the last 12 months to enable you to hurdle the roadblocks preventing the development of clinically safe and effective antigen-specific immunotherapies for autoimmune and immune mediated disorders.
To know more about 4th Antigen Specific Immune Tolerance Summit (ASIT) please click here.

Gene Therapy Medical Affairs
2021-02-09 - 2021-02-11 | Digital Event
The inaugural Gene Therapy Medical Affairs Summit is dedicated to exploring the pivotal internal and external role that Medical Affairs plays in delivering gene therapies to patients.
Industry pioneers from leading pharma and biotech companies at various stages of development and commercialization including Novartis Gene Therapy, Orchard Therapeutics & Bluebird Bio will share how to engage effectively with internal clinical and commercial teams as well as external HCPs, regulators and patient advocates to create a cohesive and streamlined launch strategy for complex, high priced gene therapy products and ultimately work to remove both barriers that exist for access to gene therapies.

Join this definitive, niche conference to delve into the unique Medical Affairs challenges encountered when working with gene therapies, from adapting to the clinical realities of the rare disease space to handling long-term follow up and post-launch scrutiny, equipping you with the insights required to launch gene therapy products more efficiently and effectively than ever before.
This virtual event is set to be a highly interactive and engaging meeting. We fully understand (and quite frankly agree) that a presentation-heavy conference just isn’t up to scratch! As such we have created a new format for this meeting which maximises opportunities for engagement, discussion, and Q&A’s in order for you to get the best value from this meeting.
To know more about Gene Therapy Medical Affairs please click here.
